Blood expression mechanism and function of TFPI2: a new biomarker for ovarian cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 25460695
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Laboratory medicine
• Research Institution: National Institute of Health Sciences (2016); Yokohama City University (2013-2015)
• Principal Investigator: ARAKAWA Noriaki 国立医薬品食品衛生研究所, 医薬安全科学部, 主任研究官 (60398394)
• Co-Investigator(Renkei-kenkyūsha): MIYAGI Etsuko 横浜市立大学, 医学部産婦人科, 教授 (40275053) ; MIYAGI Etsuko 福島県立医科大学, 医学部衛生学・予防医学講座, 助教 (20626767)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 卵巣がん / 明細胞がん / TFPI2 / バイオマーカー

Outline of Final Research Achievements

In this study, we examined relationship between TFPI2 and OCCC by investigating mechanisms underlying blood expression of TFPI2 in OCCC patients, and sought to evaluate the serum biomarker performance of TFPI2 in preoperative prediction of OCCC. TFPI2 gene was highly expressed in tumor tissues from OCCC patients. Unlike other cancer cell lines, and hypermethylation of TFPI2 promoter was undetected in OCCC-derived cell lines. Gene knockdown experiments showed that p53 is a more likely candidate for transcription factor involved in the characteristic expression of TFPI2 in OCCC. Serum TFPI2 was specifically elevated in OCCC patients, consistent with the gene expression level in the tumor tissues. These results suggest that TFPI2 is a useful serum biomarker for clinical diagnosis of OCCC.

Free Research Field

プロテオミクス